Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors
AssigneeTheryte Limited
InventorsHilmar Meek Warenius, Laurence Anthony Seabra
Life of this patent
Estimating the term…
Abstract
Provided is a method for measuring the sensitivity of a cancer cell to an anticancer agent, which method comprises testing a sample for the mutational status, expression, and/or function of a negative signal transduction factor (NSTF), and testing the sample for the mutational status, expression, and/or function of a positive signal transduction factor (PSTF), wherein when the method comprises measuring the radiosensitivity of wild-type p53 cancer cells by testing a sample comprising wild-type p53 cells or an extract therefrom for the abundance of Raf-1 protein by Western blotting, an antibody specific to Raf-1 protein is employed.
Claims12
A method for predicting the sensitivity of cancer cells to a chemotherapeutic agent, which method comprises:
- (a) testing a sample of said cancer cells for the expression level of a negative signal transduction factor (NSTF);
- (b) testing said sample for the expression level of a positive signal transduction factor (PSTF);
- (c) correlating said NSTF and PSTF expression levels with said sensitivity and
- (d) predicting said sensitivity of said cancer cells to said chemotherapeutic agent based on said correlation.
Dependencies are inferred from the claim text.